Shares of Madrigal Pharmaceuticals (MDGL 17.62%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter and full-year 2024 results before the market opened.Madrigal reported fourth-quarter revenue of 103.3million,allofwhichstemmedfromsalesofRezdiffra,thefirstdrugapprovedfortreatingmetabolicdysfunction−associatedsteatohepatitis(MASH).ThecompanypostedanetlossinQ4of59.4 million, or $2.71 ...